AstraZeneca and Merck & Co have presented more detailed data confirming Lynparza’s benefits as a frontline combination therapy in prostate cancer regardless of mutation status, paving the way for a major expansion of its use.
The partners first unveiled topline data from the PROpel Phase III trial in September last year but have now released...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
